Table 2.
Baseline Characteristics of All Metastatic RCC Patients by Utilization of an Oral Anticancer Drug in the 12 Months Following Metastatic Diagnosis (N = 2792)
| Variable | OAA use | No OAA use | p-value |
| N (row %) | 907 (32.5%) | 1,885 (68.5%) | |
| Characteristics | |||
| Age at metastatic diagnosis | < 0.001 | ||
| 66–70 | 288 (40.1) | 431 (59.9) | |
| 71–75 | 278 (38.8) | 439 (61.2) | |
| 76–80 | 207 (34.6) | 392 (65.4) | |
| 81+ | 134 (17.7) | 623 (82.3) | |
| Race/ethnicity | < 0.001 | ||
| Black Non-Hispanic | 48 (24.6) | 147 (75.4) | |
| Hispanic | 114 (37.7) | 188 (62.3) | |
| White Non-Hispanic | 665 (31.6) | 1438 (68.4) | |
| Other | 80 (41.7) | 112 (58.3) | |
| Sex | < 0.001 | ||
| Female | 337 (28.6) | 840 (71.4) | |
| Male | 570 (35.3) | 1045 (64.7) | |
| Initial Stage at SEER dx | < 0.001 | ||
| I | 77 (27.7) | 201 (72.3) | |
| II | 29 (31.5) | 63 (68.5) | |
| III | 149 (42.6) | 201 (57.4) | |
| IV | 621 (31.2) | 1368 (68.8) | |
| Unknown | 31 (37.3) | 52 (62.6) | |
| Histology | < 0.001 | ||
| Other | 99 (20.1) | 393 (79.9) | |
| Clear cell histology | 808 (35.1) | 1492 (64.9) | |
| Married | 536 (37.1) | 908 (62.9) | < 0.001 |
| Lives in metropolitan area | 731 (32.9) | 1492 (67.1) | 0.375 |
| Geographic region | < 0.001 | ||
| Midwest | 106 (31.0) | 236 (69.0) | |
| Other | 68 (31.6) | 147 (68.4) | |
| Northeast | 156 (27.7) | 407 (72.3) | |
| South | 141 (28.6) | 351 (71.3) | |
| West | 436 (36.9) | 744 (63.1) | |
| Medicaid Dual enrolled | 277 (32.4) | 578 (67.6) | 0.947 |
| Residential zip code-level characteristics | |||
| Highest quartile: residents of black race | 195 (28.5) | 490 (71.5) | 0.010 |
| Highest quartile: adults 25 + with less than high school education | 242 (35.3) | 443 (64.7) | 0.067 |
| Highest quartile: households living below poverty level | 211 (30.8) | 474 (69.2) | 0.279 |
| Nephrectomy in 12 months prior to metastatic dx | 0.044 | ||
| Partial | 17 (34.7) | 32 (65.3) | |
| Radical | 100 (39.4) | 154 (60.6) | |
| Myocardial infarction | 87 (30.5) | 198 (69.5) | 0.456 |
| Hypertension | 803 (33.3) | 1610 (66.7) | 0.024 |
| Peripheral vascular disease | 221 (29.0) | 540 (71.0) | 0.017 |
| Congestive heart failure | 187 (28.7) | 465 (71.3) | 0.018 |
| Dementia | 13 (10.4) | 112 (89.6) | < 0.001 |
| Cardiovascular disease | 177 (27.2) | 473 (72.8) | 0.001 |
| Chronic obstructive pulmonary disease | 285 (31.4) | 623 (68.6) | 0.390 |
| Cardiovascular disease | 177 (27.2) | 473 (72.8) | 0.001 |
| Rheumatologic disease | 42 (30.2) | 97 (69.8) | 0.557 |
| Peptic ulcer disease | 28 (32.2) | 59 (67.8) | 0.951 |
| Mild liver disease | 147 (35.0) | 273 (65.0) | 0.232 |
| End stage renal disease | 259 (30.8) | 583 (69.2) | 0.200 |
| Diabetes with complications | 159 (35.7) | 286 (64.3) | 0.110 |
| Hemiplegia or paraplegia | 15 (21.1) | 56 (78.9) | 0.038 |
| Year of metastatic diagnosis | < 0.001 | ||
| 2007 | 77 (31.3) | 169 (68.7) | |
| 2008 | 73 (27.9) | 189 (72.1) | |
| 2009 | 59 (22.9) | 198 (77.0) | |
| 2010 | 72 (27.0) | 195 (73.0) | |
| 2011 | 108 (33.7) | 212 (66.3) | |
| 2012 | 120 (35.6) | 217 (64.4) | |
| 2013 | 153 (39.0) | 239 (61.0) | |
| 2014 | 123 (31.6) | 266 (68.4) | |
| 2015 | 122 (37.9) | 200 (62.1) |